A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890 | Recruiting

• 2 other identifiers: 2025P002530R01EY038655-01
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.

Conditions

Fuchs Endothelial Corneal Dysfunction; Open Angle Glaucoma (OAG); Dry Eye Disease (DED); Keratoconus; Lasik Eye Surgery

Keywords

cornea; biomechanics; brillouin microscopy

Outcome Measures

Primary Outcomes (1)

• Number of subjects to successfully complete Brillouin measurement without serious unanticipated adverse events related to application of the device.

  Number and percentage of enrolled subjects who complete the single Brillouin imaging session without experiencing a serious unanticipated adverse event related to the investigational Brillouin Ocular Scanner, as determined by study staff monitoring during and immediately following the imaging procedure.

  Through completion of the single study visit, approximately 1-2 hours

Study Arms (2)

Control Group

Healthy Subjects

Patient Group

Patient Subjects (Fuch's endothelial dystrophy, Corneal guttae, Open-angle glaucoma, Dry eye disease, Keratoconus, post-LASIK)

Eligibility Criteria

• Age: 20 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Aim 1 - Control Group (Healthy Subjects) : 10 subjects per 6 age ranges (20-29yr, 30-39yr, 40-49yr, 50-59yr, 60-69yr, 70-79yr), total 60 subjects Aim 2 - Patient Groups : 20 patients per 6 diseases (Moderate Fuchs' endothelial dystrophy, Early-stage isolated corneal guttae, Primary open-angle glaucoma, Dry eye disease, Keratoconus, post-LASIK), total 120 patients.

You may qualify if:

• Healthy volunteers with normal eyes
• Visual acuity between +2 to -6 diopters

You may not qualify if:

• History of refractive or cataract surgery
• History of ocular disease
• Active non-ophthalmic systemic disease

Sponsors & Collaborators

• Massachusetts General Hospital: lead
• National Eye Institute (NEI): collaborator
• Massachusetts Eye and Ear Infirmary: collaborator

Study Sites (1)

Massachusetts General Brigham

Boston, Massachusetts, 02114, United States

RECRUITING

Related Publications (3)

• Ryu S, Martino N, Kwok SJJ, Bernstein L, Yun SH. Label-free histological imaging of tissues using Brillouin light scattering contrast. Biomed Opt Express. 2021 Feb 17;12(3):1437-1448. doi: 10.1364/BOE.414474. eCollection 2021 Mar 1.

  PMID: 33796364 BACKGROUND

• Eltony AM, Shao P, Yun SH. Measuring mechanical anisotropy of the cornea with Brillouin microscopy. Nat Commun. 2022 Mar 15;13(1):1354. doi: 10.1038/s41467-022-29038-5.

  PMID: 35293388 BACKGROUND

• Chow DM, Yun SH. Pulsed stimulated Brillouin microscopy. Opt Express. 2023 Jun 5;31(12):19818-19827. doi: 10.1364/OE.489158.

  PMID: 37381389 BACKGROUND

MeSH Terms

Conditions

Glaucoma, Open-Angle; Dry Eye Syndromes; Keratoconus; Corneal Diseases

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases; Lacrimal Apparatus Diseases

Study Officials

• Seok-Hyun Yun, PhD

  Massachusetts General Brigham

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Soyeon (Selina) Ahn, PhD

CONTACT

3396009736; sahn14@mgh.harvard.edu

Seok-Hyun Yun, PhD

CONTACT

6177688704; syun@mgh.harvard.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 18, 2026
• First Posted: August 24, 2026
• Study Start: August 18, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: August 25, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)